Arca
Skip to content
Tools
Tools

Anxiety

Drug research and approvals for anxiety: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,218 studies of anxiety are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 1,218
  • Trials authorized in Canada: 12
  • FDA orphan approvals: 0
  • EU medicines: 9

Recruiting now

Newest posted first, of 1,218 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 20

  • AlprazolamGABA-A receptor; anion channel positive allosteric modulator
  • LorazepamGABA-A receptor; anion channel positive allosteric modulator
  • EscitalopramSerotonin transporter inhibitor
  • DiazepamGABA-A receptor; anion channel positive allosteric modulator
  • HydroxyzineHistamine H1 receptor antagonist
  • BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
  • ClobazamGABA-A receptor; anion channel positive allosteric modulator
  • OxazepamGABA-A receptor; anion channel positive allosteric modulator
  • BromazepamGABA receptor alpha-2 subunit positive allosteric modulator
  • ChlordiazepoxideGABA-A receptor; anion channel positive allosteric modulator
  • Clorazepic acidGABA-A receptor; anion channel positive allosteric modulator
  • ProchlorperazineDopamine D2 receptor antagonist
  • TrifluoperazineSerotonin 2a (5-HT2a) receptor antagonist
  • MeprobamateGABA-A receptor; anion channel agonist
  • PrazepamGABA-A receptor; anion channel positive allosteric modulator
  • HalazepamGABA-A receptor; anion channel positive allosteric modulator
  • Mebutamate
  • ClotiazepamGABA-A receptor; anion channel positive allosteric modulator
  • Ketazolam
  • Medazepam

Phase 3 12 of 100

Phase 2 12 of 30

Phase 1 or earlier 12 of 16

How its trials ended

2,985 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 494 whose ending is known, 57% met their primary endpoint, 8% missed it and 35% stopped early.

  • Completed, result not reported1,46149%
  • Ongoing68723%
  • Status unknown34311%
  • Met its primary endpoint2829%
  • Stopped: other or unclear1134%
  • Missed its primary endpoint381%
  • Stopped: enrollment or feasibility311%
  • Stopped: sponsor or business decision11<1%
  • Stopped: funding11<1%
  • Stopped: lack of efficacy6<1%
  • Stopped: safety2<1%

Trials authorized in Canada

The 10 newest of 12; search them all in Canada trials
Jul 23, 2024Treatment with l-methylfolate for treatment-resistant generalized anxiety disorder: a pilot studyMethylfolateQueens UniversityPending
Apr 24, 2024Psilocybin-assisted existential, attachment and relational (PEARL) therapy for caregivers of patients with advanced cancer: a phase II open-label trialPsilocybinUniversity Health NetworkOngoing
Jan 18, 2024A phase 2a, placebo-controlled randomized, double-blind trial to evaluate the safety, tolerability, and preliminary efficacy of psilocybin oral solution in…PsilocybinDr. Claudio SoaresOngoing
Jan 12, 2023A 2-part, phase 2a, randomized, double-blind trial to evaluate the safety, tolerability, and efficacy of psilocybin oral solution in adults with generalized…PsilocybinDiamond TherapeuticsPending
Aug 3, 2022Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)PsilocybinBrain and Cognition Discovery FoundationClosed
Mar 16, 2021A randomized placebo-controlled trial of sertraline vs. placebo in the treatment of anxiety in children and adolescents with neurodevelopmental disordersSertralineDr Evdokia AnagnostouOngoing
Jul 24, 2019Cannabidiol for the treatment of anxiety disorders: an 8-week pilot studyTN-C200M2 (cannabidiol) / TN-TC11M2 (cannabidiol - DELTA-9-tetrahydrocannabinol)Macanxiety Research CentrePending
Jul 4, 2019Chi-902 (cannabis oil) for treatment of social anxiety disorder - a phase IIb randomized double-blind placebo-controlled clinical trialCHI-902 (DELTA-9-tetrahydrocannabinol - cannabidiol)Canopy Health Innovations IncClosed
Jan 28, 2019The safety, efficacy and tolerability of microbial ecosystem therapeutic-2 in people with majoy depression and/or generalized anxiety disorderMET-2 (microbial ecosystem therapeutic-2)NubiyotaPending
Feb 2, 2018Open label 8-week study of prazosin use in adults with anxiety disordersPrazosinUniversity of ManitobaOngoing

Medicines authorised in the EU

Newest first

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.